ProCE Banner Activity

NICHE-3: Phase II Trial of Neoadjuvant Nivolumab + Relatlimab for Locally Advanced dMMR Colon Cancer

Conference Coverage

In the phase II NICHE-3 trial, neoadjuvant nivolumab + relatlimab resulted in a 79% pCR rate for patients with locally advanced dMMR colon cancer with no surgical delays.

Released: October 26, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc